One of the things that makes developing effective treatments for Parkinson's disease so challenging is its complexity. While some forms are caused by genetics, others have environmental factors, and ...

The U.S. Department of Health and Human Services (HHS) announced a significant policy shift Wednesday, releasing official ...

Scientists argue that Parkinson's disease complexity demands a new way of classifying the disease for research purposes, one based not on clinical diagnosis but biology. The authors have called their ...

Parkinson's disease (PD) and dementia with Lewy bodies are currently defined by clinical features, which can be heterogeneous and do not capture the presymptomatic phase of neurodegeneration. Recent ...

Just as fluid biomarkers for amyloidosis and tau have revolutionized clinical studies of Alzheimer’s disease, α-synuclein markers are poised to do the same for Parkinson’s. With the advent of ...